Recash test site | Mohammad Carlsen | Activity https://recash.wpsoul.net/members/potbubble8/activity/ Activity feed for Mohammad Carlsen. Wed, 20 May 2026 23:39:59 +0000 https://buddypress.org/?v= en-US 30 hourly 2 9fb5a2534d0a6a863cb69743ae6660a8 Mohammad Carlsen posted an update: Lenvatinib (Len) plus everolimus (Eve) is an approved therapy […] https://recash.wpsoul.net/activity/p/51530/ Wed, 11 Dec 2024 15:22:25 +0000 Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), but limited data exist on the efficacy of Len ± Eve after progression on immune checkpoint inhibitors (ICIs) and VEGFR-TKIs.

We…[Read more]

]]> 0 8ee3477736b81e89292e8c9b5158e50c Mohammad Carlsen became a registered member https://recash.wpsoul.net/activity/p/51160/ Wed, 11 Dec 2024 14:58:44 +0000 0